Latest News & Features
Americas
In this session, Will James and Tim Harris will discuss their personal experiences litigating life sciences cases before the UPC. They will share their substantive and procedural insights, as well as strategic considerations and pitfalls to avoid. 24 December 2024
Americas
The Unified Patent Court (UPC) opened for business in June 2023. In this session, Ravi Srinivasan, partner at JA Kemp, explains how UPC litigation has been shaping up over the past year and shares practical tips based on experiences so far. 24 December 2024
Americas
Long-recognised, unwritten jurisdictional norms have seen questions of validity and infringement of registered IP rights reserved to the courts of the country of registration. 22 December 2024
Americas
Bethan Hopewell, Joel Coles, and Siddharth Kusumakar, partners at Powell Gilbert, discuss the significant developments in the European patent landscape in 2024, not only at the UPC but also at the EPO. 22 December 2024
Americas
The integration of cutting-edge medical technology within the life sciences has ushered in an era of unprecedented innovation, transforming the landscape of healthcare and patient wellbeing. 20 December 2024
Americas
Machine learning can be an invaluable tool in drug discovery for target identification, compound screening, and predictive modeling. The use of AI can accelerate drug discovery timelines, reduce costs and enhance therapeutic outcomes. 19 December 2024
Americas
Speakers from Philips Ormonde Fitzpatrick, Axinn Veltrop & Harkrider, and Leason Ellis discuss how IP rights are not merely legal tools but strategic assets that can significantly influence a product’s lifecycle, from development to market. 19 December 2024
Americas
Speakers from Mammoth Biosciences, Cargo Therapeutics, Star Therapeutics, and Greenberg Traurig, discuss academia and industry, technology transfer, and leveraging research for commercialisation. 19 December 2024
Americas
Pair of generic drug makers challenged validity of patent on priority, novelty and inventive step | EPO found the patent did not introduce any new matter not originally disclosed in the pharma company’s application. 19 December 2024
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg. 19 December 2024